MTOR and prostate cancer: Similarly, although synergistic effect by erlotinib and BKM120 has not been reported, combinations of erlotinib and PI3K/mTOR inhibitors showed synergistic cytotoxicity in cells of prostate cancer, NSCLC and ovarian cancer in previous studies [42–44].